所有癌症患者，包括转移性癌症患者，都被鼓励进行体育活动。本文研究了针对与转移性前列腺癌男性的有氧运动干预的次要终点。ExPeCT(运动、前列腺癌和循环肿瘤细胞)是一个多中心随机对照试验，其中包括6个月的有氧运动干预组和标准护理对照组。运动的依从性数据通过心率监测器收集。在基线、3个月和6个月时，评估了生活质量(FACT-P)和身体活动(自行问卷)。共纳入61名患者(年龄69.4±7.3岁，身体质量指数29.2±5.8 kg/m2)。患病时间的中位数为34个月(IQR 7-54)。共有35例(55%)患者的≥1个部位受到转移性疾病的影响。没有患者报告任何不良事件。运动对生活质量无影响(Cohen's d=-0.082)。总的监督运动课程遵守率为83%(参与者参加了396次可能的课程中的329次)。非监督家庭运动课程的总遵守率为72%(1-3个月)和67%(3-6个月)。整体身体活动得分的建模结果显示，组别(p值=0.25)和时间(p值=0.24)都没有显著的主要影响。在一组患有高负担转移性前列腺癌的患者中，6个月的有氧运动干预没有改变生活质量。需要进一步的运动研究，以检查运动在与转移性前列腺癌患者一起生活中的作用。该试验已在临床试验登记（NCT02453139）于2015年5月25日。©2023。作者(们)。

All patients living with cancer, including those with metastatic cancer, are encouraged to be physically active. This paper examines the secondary endpoints of an aerobic exercise intervention for men with metastatic prostate cancer.ExPeCT (Exercise, Prostate Cancer and Circulating Tumour Cells), was a multi-centre randomised control trial with a 6-month aerobic exercise intervention arm or a standard care control arm. Exercise adherence data was collected via heart rate monitors. Quality of life (FACT-P) and physical activity (self-administered questionnaire) assessments were completed at baseline, at 3 months and at 6 months.A total of 61 patients were included (69.4 ± 7.3 yr, body mass index 29.2 ± 5.8 kg/m2). The median time since diagnosis was 34 months (IQR 7-54). A total of 35 (55%) of participants had > 1 region affected by metastatic disease. No adverse events were reported by participants. There was no effect of exercise on quality of life (Cohen's d =  - 0.082). Overall adherence to the supervised sessions was 83% (329 out of 396 possible sessions attended by participants). Overall adherence to the non-supervised home exercise sessions was 72% (months 1-3) and 67% (months 3-6). Modelling results for overall physical activity scores showed no significant main effect for the group (p-value = 0.25) or for time (p-value = 0.24).In a group of patients with a high burden of metastatic prostate cancer, a 6-month aerobic exercise intervention did not lead to change in quality of life. Further exercise studies examining the role of exercise for people living with metastatic prostate cancer are needed.The trial was registered at clinicaltrials.gov (NCT02453139) on May 25th 2015.© 2023. The Author(s).